Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 5,371 | 547 | 4,770 |
| Samples | 523 | 79 | 439 |
| Peptides | 427 | 60 | 374 |
Function
OPRM1 · Opioid receptor mu 1
This gene encodes one of at least three opioid receptors in humans; the mu opioid receptor (MOR). The MOR is the principal target of endogenous opioid peptides and opioid analgesic agents such as beta-endorphin and enkephalins. The MOR also has an important role in dependence to other drugs of abuse, such as nicotine, cocaine, and alcohol via its modulation of the dopamine system. The NM_001008503.2:c.118A>G allele has been associated with opioid and alcohol addiction and variations in pain sensitivity but evidence for it having a causal role is conflicting. Multiple transcript variants encoding different isoforms have been found for this gene. Though the canonical MOR belongs to the superfamily of 7-transmembrane-spanning G-protein-coupled receptors some isoforms of this gene have only 6 transmembrane domains. [provided by RefSeq, Oct 2013].
Isoforms & Proteins
16 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000434900 | P35372-10 | 423 | 272 |
| ENST00000229768 | P35372-3 | 416 | 254 |
| ENST00000330432 | P35372 | 410 | 241 |
| ENST00000360422 | L0E130* | 402 | 250 |
| ENST00000337049 | P35372-5 | 385 | 234 |
| ENST00000428397 | P35372-2 | 374 | 225 |
| ENST00000414028 | P35372-4 | 372 | 226 |
| ENST00000419506 | P35372-9 | 372 | 226 |
| ENST00000452687 | P35372-7 | 370 | 225 |
| ENST00000435918 | P35372-8 | 367 | 222 |
| ENST00000524163 | P35372-11 | 366 | 221 |
| ENST00000518759 | P35372-13 | 282 | 181 |
| ENST00000520708 | P35372-12 | 277 | 177 |
| ENST00000522236 | P35372-12 | 277 | 177 |
| ENST00000522555 | P35372-12 | 277 | 177 |
| ENST00000520282 | E7EW71* | 1 | 1 |
Gene Properties
Recurrent Mutations
All 272 amino-acid changes on canonical ENST00000434900 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in OPRM1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in OPRM1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 5/133 4% |
| Endometrial Carcinoma | 4/42 10% | 20/612 3% |
| Non-Small Cell Lung Carcinoma | 28/304 9% | 29/1390 2% |
| Squamous Cell Lung Carcinoma | 6/57 11% | 19/810 2% |
| Melanoma | 0/210 0% | 54/1899 3% |
| Germ Cell Tumour | 3/25 12% | 1/169 1% |
| Other Solid Cancers | 3/94 3% | 30/1515 2% |
| Rhabdomyosarcoma | 0/33 0% | 4/171 2% |
| Colorectal Carcinoma | 6/143 4% | 60/3239 2% |
| Adrenocortical Carcinoma | 0/3 0% | 2/112 2% |
| Cervical Carcinoma | 0/35 0% | 7/422 2% |
| Gastric Carcinoma | 1/74 1% | 22/1809 1% |
| Esophageal Carcinoma | 0/23 0% | 9/769 1% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 29/2550 1% |
| Hepatocellular Carcinoma | 0/46 0% | 24/2210 1% |
| Head and Neck Carcinoma | 1/85 1% | 16/1574 1% |
| Non-Cancerous | 0/104 0% | 9/830 1% |
| Neuroendocrine Tumour | 5/154 3% | 2/577 0% |
| Bladder Carcinoma | 0/58 0% | 9/956 1% |
| Plasma Cell Myeloma | 1/44 2% | 2/305 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 5/752 1% |
| Glioma | 0/52 0% | 14/2127 1% |
| Ovarian Carcinoma | 4/109 4% | 3/998 0% |
| Ewings Sarcoma | 0/63 0% | 2/262 1% |
| Breast Carcinoma | 2/144 1% | 17/3264 1% |
| Other Sarcomas | 2/69 3% | 2/699 0% |
Mutation Distribution
Where OPRM1 is mutated · all tissues, split by cell line vs tissue
How many mutations in OPRM1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 16 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 5,371 mutations in OPRM1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|